Two of FDA’s vaccine regulators will be leaving in the fall of 2021, which has the potential to impact COVID-19 vaccine recommendations for both children under the age of 12 and booster shots.
In the fall of 2021, two of FDA’s vaccine regulators will be leaving, which may potentially impact COVID-19 vaccine regulations—including vaccine recommendations for children under the age of 12 and booster shots recommendations—according to an Aug. 31, 2021, article in The New York Times. In a Tuesday email to the staff cited in the same article, it was revealed that Marion Gruber, the director of FDA’s vaccines office, will retire in October. Philip Krause, Gruber’s deputy, will leave in November.
As stated in The New York Times article, their departure could have been in part due to the Biden administration encouraging adults to get a booster vaccine eight months after receiving their second shot. According to anonymous individuals close to the situation referenced in the article, Gruber and Krause believed there was not enough data to justify offering booster shots yet.
According to an Aug. 31, 2021 memo shared with The Washington Post, Peter Marks, director of the Center for Biologics Evaluation and Research, FDA, will be the acting head of the vaccine office while FDA searches for a replacement.
Sources: The New York Times, The Washington Post
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.